Found 95 articles
Nanoscope Awarded $1.5M Phase 2B SBIR Grant to Advance Ambient Light Activatable Opsin Gene Therapy to Restore Vision for AMD Patients
Nanoscope researchers were awarded a $1.5 million Phase 2b Small Business Research Innovation (SBIR) grant by the National Eye Institute (NEI) of the National Institutes of Health (NIH) to advance the company's ambient light activatable optogenetic gene therapy for age-related macular degeneration (AMD).
Nanoscope Therapeutics Announces Presentation of Positive Results from Optogenetic Gene Therapy for Retinal Degenerative Diseases at the EURETINA 2021 Virtual Conference
Nanoscope Therapeutics Inc., today announced Dr. Santosh Mahapatra, principal investigator of the company's clinical study on optogenetic gene therapy for vision restoration in people blinded by different gene mutations including ABCA4, will present findings from the study at the EURETINA 2021 Virtual Conference September 9 – 12.
Nanoscope Therapeutics Announces First Patient Dosed in Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa
Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal degenerative diseases, announced that the first patient had been dosed in its Phase 2b clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with retinitis pigmentosa.
The U.S. FDA has had a mix of announcements this week, from drug approvals to the acceptance of NDAs and INDs. Here’s a look.
Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa
Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal degenerative diseases, announced that its Investigational New Drug application is now open for Phase 2b clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with advanced retinitis pigmentosa.
Nanoscope's Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosa
Nanoscope Therapeutics Inc today announced that vision improvements for all evaluated advanced retinitis pigmentosa (RP) patients persisted through one year following a single intravitreal injection in a Phase 1/2a clinical study with MCO.
Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for treatment of inherited retinal diseases, today announced an expansion of its Clinical Advisory Board with the appointment of four new members.
Nanoscope's Optical Gene Therapies to be Featured at Optogenetics and Optical Manipulation 2021 Conference
Researchers of Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal diseases, will make multiple scientific presentations featuring its groundbreaking research on optical gene delivery and opsin based neuromodulation therapy at the Optogenetics and Optical Manipulation 2021 virtual conference,
Nanoscope President to Deliver Talk on Gene Therapy for Retinal Diseases at Association for Ocular Pharmacology and Therapeutics Conference
Company's lead product, an optogenetic gene therapy to restore vision for patients with retinitis pigmentosa, expected to enter seminal clinical trials in 2021
Nanoscope® team conferred Phase II Retinal Organoid Challenge (ROC) award by National Institute of Health
To meet the advance challenge for generating a physiologically relevant three-dimensional (3D) retinal organoid, Nanoscope researchers® in collaboration with University of Colorado, and Miami University were recently awarded the top prize from the 3D-ROC challenge by the National Institute of Health (NIH).
NANOSCOPE THERAPEUTICS Inc., a clinical-stage biotechnology company determined to change lives through the ocular gene therapy, today announced that it has received an Orphan drug designation from FDA for gene therapy-based treatment of Stargardt disease, a form of inherited retinal degenerative disease caused by gene mutation and passed on to children.
NANOSCOPE THERAPEUTICS Announces Presentation at the 2020 Annual Meeting of American Academy of Ophthalmology
NANOSCOPE THERAPEUTICS Inc., a clinical-stage biotechnology company determined to change lives through the ocular gene therapy based on its proprietary ambient light activatable MCO Optogenetic Technology Platform, today announced that an oral presentation at the Late Breaking Developments session of Retina Subspecialty Day will
2019 SPIE Startup Challenge Semi-Finalists to Showcase Photonics Innovations in Healthcare, Lasers, Wearables, and IoT
Thirty-five photonics business startups from seven countries will participate in the 2019 SPIE Startup Challenge semi-finals, held during SPIE Photonics West on 5 February.
Amend Surgical Signs Exclusive License Agreement With University Of Florida Research Foundation For Biomimetic Bone